Genelabs, Taiwan National Health Research Institutes and Genovate To Co-Develop New Hepatitis C Treatment
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Genelabs Technologies inked a development agreement with the Taiwan National Health Research Institutes and Genovate Biotechnology to co-develop drugs to treat hepatitis C, the company announced July 23
You may also be interested in...
GSK’s Genelabs Acquisition To Focus On Hepatitis C Compounds
Despite the tough capital environment, Genelabs gets $1.30 per share, restoring much of the value its stock lost during 2008.
GSK’s Genelabs Acquisition To Focus On Hepatitis C Compounds
Despite the tough capital environment, Genelabs gets $1.30 per share, restoring much of the value its stock lost during 2008.
China’s HCV Drug Market To Grow To $150 Million By 2012
SHANGHAI - China's hepatitis C virus drug market will grow to $150 million by 2012, according to a report released in September by Decision Resources